Safety and Efficacy of Using a Novel Full Visual Access Platform System in Transvaginal Hysterectomy

Prior treatment

• Uterine volume ≥20 weeks, history of pelvic inflammatory disease, severe endometriosis, degree III or IV uterine prolapse; Previous surgical history of intestinal obstruction, recurrent pelvic inflammatory disease, pelvic tuberculosis, and pelvic abdominal tumor; Gynecological examination of the uterine and rectal fossa is completely closed;
• Known to have participated in any other clinical trial or taken hormone therapy within 3 months;

Other illness

• Preoperative examination for malignant possibility
• Patients with known blood disorders, coagulation disorders, active bleeding at any site, or bleeding propensity;
• complicated with serious diseases of central nervous system, cardiovascular system, liver and kidney, digestive tract, respiratory system, endocrine and metabolism (thyroid disease, Cushing\'s syndrome, hyperprolactinemia), skeletal and muscular system and mental disorders;
• patients with acute infection;

Other

• Pregnant and lactating women;
• asexual life history, vaginal malformations or adhesions, postmenopausal vaginal atrophy and stenosis;
• Patients known to have severe hepatic or renal dysfunction;
• who cannot sign the informed consent;
• For those with known or suspected poor compliance who could not complete the trial.

• Female patients ≤ 60years old
• Patients requiring total hysterectomy (with or without bilateral adjuncts or salpingectomy) due to uterine fibroids
• BMI ranges from 18.5 to 27.9kg/m2;
• Informed consent signed by the subject himself or his legal representative.